Everything below concerns 肠促胰素. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-08-18. Where a claim depends on a specific study, the study is described rather than over-claimed.
Identity and purity are established with reversed-phase high-performance liquid chromatography and mass spectrometry. Chromatographic profiles reveal related impurities, truncated sequences, and oxidation products, while mass measurement confirms the expected molecular mass. Purity values for research material are typically reported as a percentage by peak area. Reference standards help calibrate retention behavior across instruments. Independent laboratories emphasize method suitability because results depend heavily on column chemistry, gradient, and detection wavelength. Batch-to-batch comparison relies on the same validated method.
Investigational peptide material is commonly distributed as a lyophilized powder in sealed vials. The solid form appears as a white to off-white cake or powder and is hygroscopic once opened. Peptides of this size are sensitive to moisture, repeated freeze-thaw cycles, and prolonged exposure to ambient light. Handling practices therefore emphasize desiccation, minimal vial opening, and cold storage. Working aliquots are often prepared to avoid repeatedly warming the bulk container.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Modified synthetic peptide | Designed to engage three receptor targets |
| Appearance | White to off-white powder | Lyophilized form supplied in sealed vials |
| Solubility | Soluble in water | Dissolves in aqueous buffer systems |
| Storage, solid | -20 °C or below | Desiccated and protected from light |
| Typical analysis | RP-HPLC with mass detection | Purity by peak area, identity by mass |
Research-grade peptide material is commonly supplied as a lyophilized powder, a form that limits degradation during transport and storage. Standard practice keeps such material cold and protected from light and moisture, with tighter conditions used for long-term archives. Once dissolved, solutions are generally considered less stable than the dry powder and are handled on shorter timescales. These established conventions derive largely from general peptide chemistry rather than from compound-specific evidence alone.
Identification and purity assessment typically rely on reversed-phase high-performance liquid chromatography, often paired with mass spectrometry. Mass measurement confirms the expected molecular mass and can reveal truncations or modifications. Peptide mapping and sequencing techniques provide sequence-level confirmation when needed. Because related peptide impurities can behave similarly in a single method, orthogonal techniques are usually combined. Reported purity values depend heavily on the method used and should be interpreted with that in mind.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
retatrutide 是一种人工合成的多肽，设计目标是同时作用于 GIP、GLP-1 与胰高血糖素三种受体。这种三重激动设计试图把多条代谢通路的调节整合进单一分子，而不是只依赖一种肠促胰素受体。分子骨架以天然肽序列为基础，经过非天然氨基酸替换和脂肪酸侧链修饰，以获得更长的作用时间。该方向属于多受体激动剂研究的一部分，与双重激动剂的工作并行推进。
三种受体在能量平衡中的分工并不相同：GLP-1 与 GIP 受体主要参与胰岛素分泌和食欲调节，胰高血糖素受体则与能量消耗及肝糖输出相关。同时激活三者可能产生叠加效应，也可能出现相互制约，具体结果取决于受体亲和力与组织分布。这种组合在理论上可能同时影响体重与血糖指标，但协同关系的细节仍处在研究阶段。
化学修饰延长了分子在体内的停留时间，使较低频次的给药安排成为可能。脂肪酸侧链通过与白蛋白结合延缓清除，非天然氨基酸则降低酶解速率。这些修饰同时改变分子的溶解性与稳定性，需要在制剂设计和储存条件中一并考虑。修饰引入的免疫原性风险也属于开发过程中需要评估的项目。
== Clinical use == Alpha-glucosidase inhibitors are used to establish greater glycemic control over hyperglycemia in diabetes mellitus type 2, particularly with regard to postprandial hyperglycemia. The intake of a single dose before a meal containing complex carbohydrates clearly suppresses the glucose spike and may decrease the postprandial hyperglycemia (higher than 140 mg/dL; >7.8 mmol/L) in patients with type II diabetes. This ability is observed in the native/raw state of the alpha-amylase inhibitor; therefore, its consumption inside a meal that undergo heating (baking, frying or cooking/boiling) is expected to blunt its property to decrease the activity of carbohydrate digesting enzymes. They may be used as monotherapy in conjunction with an appropriate diabetic diet and exercise, or they may be used in conjunction with other anti-diabetic drugs. A Cochrane systematic review assessed the effect of AGIs in people with impaired glucose tolerance, impaired fasting blood glucose, elevated glycated hemoglobin A1c (HbA1c). It was found that Acarbose appeared to reduce incidence of diabetes mellitus type 2 when compared to placebo, however there was no conclusive evidence that acarbose compare to diet and exercise, metformin, placebo, no intervention improved all-cause mortality, reduced or increased risk of cardiovascular mortality, serious or non-serious adverse events, non-fatal stroke, congestive heart failure, or non-fatal myocardial infarction.
On April 17, Ty Cobb, a former member of Trump's legal counsel during his first term in office, claimed that Trump displayed symptoms of dementia, characterizing the linguistic changes displayed in the Truth Social posts as "suggestive of the absence of any frontal lobe controls." Cobb additionally highlighted the late-night timestamps of the posts and Trump's apparent dozing off at Cabinet meetings as aligning with sleep cycle reversals seen in Alzheimer's disease, claiming that the combination of these behavioral traits characterized an acceleration in cognitive decline. White House spokesman David Ingle responded to both Crockett and Cobb's comments by praising Trump's "sharpness, unmatched energy, and historic accessibility" while accusing Crockett of aiding in an alleged cover-up of Joe Biden's mental decline as president and characterizing Cobb as "[a] severe case of Trump Derangement Syndrome." NATO official Paul Fritch also contested the mental illness characterization, speculating that Trump's behavior was instead the result of frustration towards his inability to bring the Iran war to a quick resolution. On June 2, journalist Aaron Rupar tweeted that Trump had made no public appearances since May 27 when he had attended a Cabinet meeting with a pre-recorded interview being released during that time, in response many commentors questioned the apparent pattern of Trump disappearing from public commitments for about a week each month.
Jerry Gallwas (born 1936) is an American rock climber active in the 1950s during the dawn of the Golden Age of Yosemite Rock Climbing. He achieved a number of pioneering first ascents including sandstone spires in the American Southwest, and the first ascent of the Northwest Face of Half Dome with Royal Robbins and Mike Sherrick in 1957. Gallwas made his own heat-treated chrome-molybdenum steel alloy pitons, which contributed to the success of the climb. Gallwas studied chemistry at San Diego State University and spent much of his career working for scientific instrument maker Beckman Instruments, Inc. He helped to develop consensus standards for laboratory medicine, and served on the board of directors and as president of the National Committee for Clinical Laboratory Standards.
SSRIs prevent 5-HT from binding to SERT which prevents absorption of 5-HT back into the presynapse terminal, where it is metabolized by monoamine oxidase or stored in secretory vesicles. As a result, the 5-HT concentration increases at the somatodendritic area of the 5-HT neuron but not so much at the axon terminal area (demonstrated in figure 2). This increase in 5-HT concentration causes desensitization of somatodendritic 5-HT1A autoreceptors. When these 5-HT1A autoreceptors have been downregulated, they will no longer restrict the impulse flow of the 5-HT neuron. The impulse flow is turned on and as a result 5-HT is released at the axon terminal. However, this increase of 5-HT does not happen quickly compared to the increase of 5-HT at the somatodendritic area of the 5-HT neuron. This delay is caused by the time it takes 5-HT to downregulate 5-HT1A autoreceptors and turn on the neuro impulse flow of the 5-HT neuron. This delay can explain the reason why antidepressants do not have effect on depression immediately. This can also be the reason why the antidepressant mechanisms can be connected to the increasing neuro impulse flow from 5-HT neurons, where as the concentration of 5-HT increases at the axon terminal before SSRIs start to work properly. When SSRIs have (1) inhibited the re-uptake pump, (2) increased somatodendritic 5-HT, (3) desensitized somatodendritic 5-HT1A autoreceptors, (4) turned on the impulse flow and (5) increased the release of 5-HT from axon terminal, the last step might be desensitization of postsynaptic 5-HT receptors.
Sources: en.wikipedia.org
The EMC of wood varies with the ambient relative humidity (a function of temperature) significantly, to a lesser degree with the temperature. Siau (1984) reported that the EMC also varies very slightly with species, mechanical stress, drying history of wood, density, extractives content and the direction of sorption in which the moisture change takes place (i.e. adsorption or desorption).
== Detection == Since 2024, an immunoassay-based point-of-care testing in the form of test strips is available for the detection of nitazenes. The drug sample is added to water and requires sufficient solubility for the test to be successful. The detection limit of the highly potent isotonitazene is given as 2000-3000 ng/mL. The test is of limited general applicability for non-nitazene benzimidazole opioids. Desnitazenes, for example, which are not substituted at the benzo structure portion, cannot be successfully tested by this method. According to the manufacturer, there is no cross-reactivity with frequently used adulterants such as acetaminophen, caffeine, diphenhydramine, other non-benzimidazole opioids (heroin, methadone, fentanyl) and common non-opioid drugs (xylazine, MDMA, cocaine, ketamine).
Lipton tea is available in over 150 countries, and particularly popular in Europe, North America, Africa and the Middle East, parts of Asia and Australasia (Australia and New Zealand), as well as Latin America, and the Caribbean. Despite its British origins, Lipton tea (such as Lipton Yellow Label) is not marketed in the United Kingdom, where brand owner Lipton Teas and Infusions sells PG Tips. Lipton Ice Tea, from the Unilever PepsiCo joint venture, is available in the United Kingdom. Lipton tea blends are selected from many different plantations around the world, from well-known producing countries, including Sri Lanka, India, Kenya, and China. Apart from the usual black leaf tea, the brand offers many other varieties, including green leaf teas, flavoured black teas, herbal teas, and milk tea in various Asian markets. The Lipton Tea Innovation & Technology Academy was launched by Lipton Teas and Infusions together with the Government of Kenya and the University of Kabianga in February 2024 to offer training varying from vocational courses to advanced degrees in tea growing and harvesting. In May 2024, Lipton Teas and Infusions announced an agreement to sell its tea estates in Kenya, Tanzania, and Rwanda to Browns Investments with the proceeds reinvested into East Africa’s tea industry.
Sources: en.wikipedia.org
Complicated silicosis is more common with accelerated silicosis than with the chronic variety. Acute silicosis Silicosis that develops a few weeks to 5 years after exposure to high concentrations of respirable silica dust. This is also known as silicoproteinosis. Symptoms of acute silicosis include more rapid onset of severe disabling shortness of breath, cough, weakness, and weight loss, often leading to death. The x-ray usually reveals a diffuse alveolar filling with air bronchograms, described as a ground-glass appearance, and similar to pneumonia, pulmonary edema, alveolar hemorrhage, and alveolar cell lung cancer.
== Constitutional and state laws == The Barger decision was made in the context of the then prevailing reserved State powers doctrine, which was itself overturned in 1920 in the Engineers case. Since 2005, Australian industrial relations laws, such as WorkChoices, have been primarily based on the corporations power in section 51(xx) of the Constitution, which enables labour laws to be of much wider reach, without the constraints imposed by the conciliation and arbitration power. The corporations power gives the federal parliament power to make laws with respect to "trading and financial corporations formed within the limits of the Commonwealth", as well as 'foreign' corporations.
When chronic granulomatous disease (CGD) is suspected, neutrophil-function testing should be carried out, and positive findings should be confirmed by genotyping. The p47phox mutation is due to a pseudogene conversion, hence it may not be detectable by standard sequencing; in these cases, an immunoblot or gene dose determination may be needed to confirm p47phox deficiency. Infections caused by the pathogens commonly associated with CGD should prompt functional or genetic screening; neonatal or early postnatal screening of potentially affected children is essential with a family history of CGD. Neutrophil function tests: These include nitroblue tetrazolium (NBT) reduction test, dihydrorhodamine (DHR) 123 test, direct measurement of superoxide production, cytochrome c reduction assay, and chemiluminescence. DHR test is usually preferred because it is easy to use, objective, and it is able to distinguish between X-linked and autosomal forms of CGD; furthermore, it allows to detect gp91phox carriers.
Chloral hydrate is a geminal diol with the formula Cl3C−CH(OH)2. It was first used as a sedative and hypnotic in Germany in the 1870s. Over time it was replaced by safer and more effective alternatives but it remained in use in the United States until at least the 1970s. It sometimes finds usage as a laboratory chemical reagent and precursor. It is derived from chloral (trichloroacetaldehyde) by the addition of one equivalent of water.
Sources: en.wikipedia.org
Solid powder is held frozen at -20 °C or below in a desiccated container. Reconstituted solutions are refrigerated and used within a limited period.
Reversed-phase liquid chromatography separates the peptide from related impurities. Mass spectrometry confirms molecular mass, which supports structural identity.
Repeated freezing and thawing can promote aggregation and precipitation of peptide material. Dividing material into single-use aliquots reduces this risk.
It is an investigational peptide that activates three hormone receptors: GIP, GLP-1 and glucagon. It is being studied mainly for obesity and type 2 diabetes, and it is not approved for any clinical use. Published information comes from controlled trials rather than from general practice.